Name of the Procedure:

Injection of Ibalizumab-uiyk, 10 mg (HCPCS Code: J1746)

Summary

Ibalizumab-uiyk is an injectable medication used to help control HIV in patients with multidrug-resistant strains. The injection works by inhibiting the HIV virus from entering immune cells, thus helping to manage the infection.

Purpose

• Medical Conditions: HIV-1 infection in patients with multidrug-resistant strains.
• Goals: To reduce the viral load in the patient's body, improve immune function, and slow down the progression of HIV.

Indications

• Symptoms/Conditions: Multidrug-resistant HIV-1 infection.
• Patient Criteria: Patients who have failed other antiretroviral therapies and have developed resistance to multiple HIV medications.

Preparation

• Pre-Procedure Instructions: Patients might not need special preparation apart from general medical history review and ensuring no contraindication to the drug. Patients should inform their healthcare provider of all medications they are currently taking.
• Diagnostic Tests: Baseline HIV viral load and CD4 cell count.

Procedure Description

1. Initial Assessment: The healthcare provider will review the patient's medical history and HIV treatment history.
2. Injection Site: The injection is administered intravenously.
3. Procedure Steps:
   • Preparation: The medication is prepared and confirmed by a pharmacist or doctor.
   • Administration: A nurse or authorized medical professional will administer the injection through a vein.
4. Tools/Equipment: Syringe, needle, and intravenous line.
5. Anesthesia/Sedation: None required.

Duration

• The injection process itself takes a few minutes, but the overall appointment may last around 1-2 hours to allow for preparation and post-injection observation.

Setting

• Typically administered in a hospital, outpatient clinic, or specialized infusion center.

Personnel

• The procedure is conducted by trained medical professionals such as doctors and nurses specializing in infectious diseases or HIV management.

Risks and Complications

• Common Risks: Redness, swelling, or pain at the injection site, dizziness, nausea.
• Rare Risks: Severe allergic reactions, infusion-related reactions.
• Management: Immediate medical attention for severe reactions, supportive care for mild to moderate side effects.

Benefits

• Expected Benefits: Reduction in HIV viral load, improved immune system function.
• Timeline: Initial positive results may be seen within weeks, with continued improvement over time.

Recovery

• Post-Procedure Care: Patients are usually monitored for a short period after the injection for any adverse reactions.
• Recovery Time: No significant downtime; patients can typically resume normal activities immediately.
• Follow-Up: Regular follow-up appointments to monitor viral load and immune function.

Alternatives

• Other Treatments: Other antiretroviral therapy options, although effectiveness may be limited due to resistance.
• Pros and Cons: Other therapies may offer different side-effect profiles and convenience (e.g., oral medications), but ibalizumab-uiyk is specifically for multidrug-resistant cases where other treatments have failed.

Patient Experience

• During Procedure: Minimal discomfort from the injection process; patients may feel slight pressure or a pinch.
• After Procedure: Possible mild side effects like dizziness or soreness, which typically resolve quickly. Pain management can include over-the-counter pain relievers and rest.